The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Hospital of Jilin University; The First Hospital of Jilin University
• Treatments: Aldesleukin; Interleukin-2

Criteria

Inclusion Criteria:

1. age <18 years old

2. meet the EULAR/PRINTO/PRES for the diagnosis of HSP

3. HIV negative;Negative for HBV and HCV.

Exclusion Criteria:

1. heart failure (cardiac function ≥ grade III NYHA)

2. liver insufficiency (upper limit of normal range of transaminase > 2 times)

3. renal insufficiency (creatinine clearance ≤30ml/min)

4. acute or severe infections such as bacteremia and sepsis

5. malignant tumor

6. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month

7. mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information

8. Intestinal ischemia or perforated gastrointestinal bleeding requires surgery

9. Inability to comply with IL-2 treatment regimen.